Barclays upgraded shares of Kenvue (NYSE:KVUE - Free Report) to a hold rating in a research report sent to investors on Thursday morning,Zacks.com reports.
KVUE has been the subject of several other research reports. Royal Bank of Canada raised shares of Kenvue from a "hold" rating to a "moderate buy" rating in a research report on Monday, December 9th. Piper Sandler upped their target price on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday. Jefferies Financial Group started coverage on Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price objective for the company. Finally, JPMorgan Chase & Co. lifted their target price on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $22.64.
Check Out Our Latest Report on KVUE
Kenvue Stock Down 0.5 %
KVUE stock traded down $0.11 during midday trading on Thursday, hitting $22.21. The company's stock had a trading volume of 9,184,286 shares, compared to its average volume of 17,639,725. The company has a market cap of $42.58 billion, a PE ratio of 40.38, a P/E/G ratio of 2.02 and a beta of 1.36. The firm's 50-day moving average is $22.95 and its 200-day moving average is $21.17. Kenvue has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue's revenue was down .4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.31 EPS. On average, equities research analysts forecast that Kenvue will post 1.07 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were given a $0.205 dividend. The ex-dividend date was Wednesday, November 13th. This represents a $0.82 annualized dividend and a yield of 3.69%. Kenvue's dividend payout ratio is currently 149.09%.
Institutional Trading of Kenvue
Several hedge funds and other institutional investors have recently bought and sold shares of KVUE. State Street Corp lifted its stake in Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares during the last quarter. Van ECK Associates Corp lifted its stake in shares of Kenvue by 110.9% during the 2nd quarter. Van ECK Associates Corp now owns 20,510,427 shares of the company's stock worth $372,880,000 after acquiring an additional 10,783,258 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Kenvue by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company's stock valued at $789,813,000 after acquiring an additional 7,546,362 shares during the period. Massachusetts Financial Services Co. MA grew its position in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company's stock valued at $2,011,832,000 after acquiring an additional 7,115,374 shares during the last quarter. Finally, Holocene Advisors LP increased its stake in Kenvue by 75.5% in the third quarter. Holocene Advisors LP now owns 13,886,454 shares of the company's stock worth $321,194,000 after purchasing an additional 5,975,392 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.
Kenvue Company Profile
(
Get Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Recommended Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.